Over the past few months, there have been exciting reports about new treatments for breast cancer. But how do you know whether they impact you? Tune into LBBC’s webinars to understand what options may be available to you now, and which could be the treatments of the future.
This past May, the FDA approved the targeted therapy alpelisib (Piqray) to treat certain hormone receptor-positive, HER2-negative breast cancers in postmenopausal women and in men. Up to 40 percent of people with metastatic hormone receptor-positive, HER2-negative breast cancer could be eligible to get the treatment, which targets a mutation on the PIK3CA gene. Join us on July 22 to hear from our speaker Adam Brufsky, MD, PhD about this new medicine, how to access it and some of the side effects that come with it.
[maxbutton id=”40″ url=”https://secure3.convio.net/lbbc/site/Calendar?view=RSVP&id=101261″ text=”CLICK HERE TO REGISTER” ]